Straits Times Index
3,176.51 -11.15 (-0.35%) Nikkei
37,068.35 -1,011.35 (-2.66%) Hang Seng
16,224.14 -161.73 (-0.99%) FTSE 100
7,895.85 +18.80 (+0.24%) Bitcoin USD
64,393.91 +816.44 (+1.28%) CMC Crypto 200
1,334.09 +21.46 (+1.64%)
LadRx Corporation (LADX)
| Previous close | 2.1000 |
| Open | 2.1000 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's range | 2.1000 - 2.1200 |
| 52-week range | 0.0600 - 10.3900 |
| Volume | |
| Avg. volume | 627 |
| Market cap | 1.05M |
| Beta (5Y monthly) | 1.67 |
| PE ratio (TTM) | 3.12 |
| EPS (TTM) | 0.6800 |
| Earnings date | 13 May 2024 - 17 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
LadRx Issues 2024 Update to Shareholders
LOS ANGELES, January 09, 2024--LadRx Corporation (OTCQB: LADX) ("LadRx" or the "Company"), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, today issued the below letter to shareholders providing a corporate update and anticipated milestones for 2024 regarding arimoclomol and LADR-7.
- Business Wire
LadRx Completes Non-Dilutive Financing Transaction for up to $11 Million with XOMA Corporation
LOS ANGELES, June 22, 2023--LadRx Corporation (OTCQB: LADX) ("LadRx" or the "Company"), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, today announced that it has transferred the royalty and milestone rights associated with arimoclomol and aldoxorubicin to XOMA Corporation (NASDAQ: XOMA) ("XOMA"). In exchange for the future rights to royalties and milestones on arimoclomol and aldoxorubicin, the agreement provides to LadRx $5 million in gros
- Business Wire
LadRx Announces Reverse Stock Split Effective as of May 17, 2023
LOS ANGELES, May 18, 2023--LadRx Corporation (OTCQB: LADX) ("LadRx" or the "Company"), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, today announced that its previously announced reverse stock split of its common stock at a ratio of 1 post-split share for every 100 pre-split shares became effective at 5:00 a.m. PDT on Wednesday, May 17, 2023. Under FINRA rules, the Company’s common stock will be traded on the OTC Capital Markets under the s
